Skip to Content
MilliporeSigma

[Vinpocetin in neurological diseases].

Ideggyogyaszati szemle (2013-01-08)
László Szapáry, Gábor Késmárky, Kálmán Tóth, Melinda Misnyovszky, Tamás Tóth, Adám Balogh, Krisztián Nagy, György Y Németh, György Németh, Gergely Fehér
ABSTRACT

Stroke is the third leading cause of death worldwide (following cardiovascular and cancer mortality) and associated with serious disability for the vast majority of patients. There is no salvage therapy for irreversibly damaged brain areas, improving the circulation of the surrounding hypoperfused areas may be associated with beneficial clinical effects. Cerebral hypoperfusion may play a role in the pathogenesis of other kind of neurological diseases, improvement of global circulation may have a preventive effect on these conditions. The aim of our study was to review the experimental and clinical articles focusing on the role of vinpocetin in different neurological conditions. Vinpocetin appears to have several different mechanisms of action that allow for its antiinflammatory, antioxidant, vasodilating, antiepileptic and neuroprotective activities in experimental conditions. On the other hand, several meta-analysis of the existing studies in acute stroke examining short and long term fatality rates with vinpocetin was unable to assess efficacy. In chronic cerebrovascular patients, vinpocetin improves impaired hemorheologic variables, has significant vasodilating properties, improves endothelial dysfunction, neuroimaging studies showed selective increase in cerebral blood flow and cerebral metabolic rate, all of which are potentially beneficial in cerebrovascular disease and may improve cognitive functions. Based on the above mentioned results, vinpocetin plays an important role both in basic research and in clinical management of different neurological diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Vinpocetine, ≥98%, solid
Vinpocetine, European Pharmacopoeia (EP) Reference Standard